Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension

Thorax

Volumn 66, Issue 4, 2011, Pages 326-332

  Soon, Elaine ^a,b   Treacy, Carmen M ^a   Toshner, Mark R ^a   MacKenzie Ross, Robert ^a   Manglam, Vijay ^c   Busbridge, Mark ^d   Sinclair McGarvie, Mark ^e   Arnold, Jayantha ^c   Sheares, Karen K ^a   Morrell, Nicholas W ^b   Pepke Zaba, Joanna ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF BUCKINGHAM   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e Institute of Actuaries   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPCIDIN; INTERLEUKIN 6; IRON; TRANSFERRIN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; FEMALE; HERITABILITY; HUMAN; IDIOPATHIC DISEASE; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON METABOLISM; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 79953027647     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.147272     Document Type: Article

References (31)

1. Deanfield J, Thaulow E, Warnes C, et al; Task Force on the Management of Grown Up Congenital Heart Disease, European Society of Cardiology; ESC Committee for Practice Guidelines. Management of grown up congenital heart disease. Eur Heart J 2003;24:1035-84.
2. Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006;48:356-65.
3. McMurray JJ. What are the clinical consequences of anemia in patients with chronic heart failure? J Card Fail 2004;10(1 Suppl):S10-12.
4. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6. (Pubitemid 34595288)
5. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic heart failure. Eur Heart J 2010;15:1872-80.
6. Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 2004;147:924-30.
7. Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
8. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4.
9. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44. (Pubitemid 30659603)
10. Lin L, Valore EV, Nemeth E, et al. Iron transferring regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007;110:2182-9. (Pubitemid 47443938)
11. Babitt JL, Huang FW, Xia Y, et al. Modulation of bone morphogenetic protein signalling in vivo regulates systemic iron balance. J Clin Invest 2007;117:1933-9. (Pubitemid 47036327)
12. Ngo K, Kotecha D, Walters JA, et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010;(1):CD007613. doi:10.1002/14651858. CD007613.pub2.
13. Ma AG, Schouten EG, Sun YY, et al. Supplementation of iron alone and combined with vitamins improves haematological status, erythrocyte membrane fluidity and oxidative stress in anaemic pregnant women. Br J Nutr 2010;104:1655-61.
14. Smith TG, Talbot NP, Privat C, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 2009;302:1444-50.
15. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-54.
16. Dingemanse J, Van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089-115. (Pubitemid 40013178)
17. Barst RJ, Langleben D, Badesch D, et al; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
18. Baynes RD. Assessment of iron status. Clin Biochem 1996;29:209-15. (Pubitemid 26142069)
19. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006;108:3204-9.
20. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001;98:8160-2.
21. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-19.
22. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002;99:4596-601. (Pubitemid 34286030)
23. Busbridge M, Griffiths C, Ashby D, et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci 2009;66:150-7.
24. Hirani V, Brookes M, McMunn A, et al. Anthropometry. In: Shaw A, McMunn A, Field J, eds. The Scottish Health Survey, 1998:13.8.4. http://www.sehd.scot. nhs.uk/scottishhealthsurvey/sh8-00.html (accessed 25 Jul 2010).
25. Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997;277:973-6. (Pubitemid 27142364)
26. Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 2008;199:215-21. (Pubitemid 351842695)
27. Westenbrink BD, Voors AA, De Boer RA, et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 2010;12:676-84.
28. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-31.
29. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-7.
30. Chambellan A, Chailleux E, Similowski T; ANTADIR Observatory Group. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005;128:1201-8. (Pubitemid 41324396)
31. Krasuski RA, Hart SA, Smith B, et al. Association of anemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol Published Online First: 14 May 2010. doi:10.1016/j.ijcard.2010.04.038.